{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:59Z","timestamp":1793661059574,"version":"4.5.1"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"InoMed project","award":["CZ.02.1.01\/0.0\/0.0\/18_069\/0010046"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/18_069\/0010046"]}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["19-07674S"],"award-info":[{"award-number":["19-07674S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.pharmthera.2020.107518","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T20:17:08Z","timestamp":1582661828000},"page":"107518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy"],"prefix":"10.1016","volume":"210","author":[{"given":"Lukas","family":"Gorecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Andrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rezacova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Korabecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.molonc.2014.10.013","article-title":"Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer","volume":"9","author":"Abdel-Fatah","year":"2015","journal-title":"Molecular Oncology"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00147","article-title":"Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan","volume":"6","author":"Abu-Sanad","year":"2015","journal-title":"Frontiers in Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107518_bb0015","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/2159-8290.CD-14-0380","article-title":"Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy","volume":"4","author":"Al-Ahmadie","year":"2014","journal-title":"Cancer Discovery"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10549-018-4683-4","article-title":"Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy","volume":"169","author":"Al-Subhi","year":"2018","journal-title":"Breast Cancer Research and Treatment"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.molonc.2015.09.009","article-title":"Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer","volume":"10","author":"Alsubhi","year":"2016","journal-title":"Molecular Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/156800961603160206122927","article-title":"Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An emerging way to enhance existing cancer therapy","volume":"16","author":"Andrs","year":"2016","journal-title":"Current Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107518_bb0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nature Reviews Cancer"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ncb3415","article-title":"ETAA1 acts at stalled replication forks to maintain genome integrity","volume":"18","author":"Bass","year":"2016","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bcp.2015.11.022","article-title":"A crucial role for ATR in the regulation of deoxycytidine kinase activity","volume":"100","author":"Beyaert","year":"2016","journal-title":"Biochemical Pharmacology"},{"issue":"19","key":"10.1016\/j.pharmthera.2020.107518_bb0050","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1128\/MCB.24.19.8504-8518.2004","article-title":"Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells","volume":"24","author":"Bindra","year":"2004","journal-title":"Molecular and Cellular Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jdermsci.2016.09.010","article-title":"Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation","volume":"84","author":"Biskup","year":"2016","journal-title":"Journal of Dermatological Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107518_bb0060","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Molecular Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0065","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10147-014-0769-0","article-title":"A phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001","volume":"20","author":"Blumenthal","year":"2015","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0070","article-title":"Targeting ATR as cancer therapy: A new era for synthetic lethality and synergistic combinations?","volume":"107450","author":"Bradbury","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107518_bb0075","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Molecular Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0080","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI122622","article-title":"Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis","volume":"129","author":"Bukhari","year":"2019","journal-title":"The Journal of Clinical Investigation"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0085","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.molcel.2010.10.030","article-title":"mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1\u03b1","volume":"40","author":"Cam","year":"2010","journal-title":"Molecular Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0090","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-07-5472","article-title":"Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance","volume":"68","author":"Chan","year":"2008","journal-title":"Cancer Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107518_bb0095","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0100","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3324\/haematol.2013.093187","article-title":"CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo","volume":"99","author":"Chaudhuri","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.biomaterials.2018.06.024","article-title":"Biodegradable PEG-poly(\u03c9-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors","volume":"178","author":"Chen","year":"2018","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molcel.2015.02.031","article-title":"ATR-mediated phosphorylation of FANCI regulates dormant origin firing in response to replication stress","volume":"58","author":"Chen","year":"2015","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cell.2011.07.049","article-title":"Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells","volume":"147","author":"Chiarle","year":"2011","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107518_bb0120","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: Therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107518_bb0125","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.bmcl.2016.04.090","article-title":"Synergistic potentiation of (\u2212)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821","volume":"26","author":"Colis","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0130","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/0008-5472.CAN-18-2807","article-title":"Inhibition of ataxia-telangiectasia mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes antitumor immunity in colorectal cancer","volume":"79","author":"Comb\u00e8s","year":"2019","journal-title":"Cancer Research"},{"issue":"27","key":"10.1016\/j.pharmthera.2020.107518_bb0135","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.1073\/pnas.0403410101","article-title":"Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases","volume":"101","author":"Cortez","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107518_bb0140","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-14-0943","article-title":"Synthetic lethal approaches exploiting DNA damage in aggressive myeloma","volume":"5","author":"Cottini","year":"2015","journal-title":"Cancer Discovery"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107518_bb0145","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.214080.113","article-title":"ATR phosphorylates SMARCAL1 to prevent replication fork collapse","volume":"27","author":"Couch","year":"2013","journal-title":"Genes & Development"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107518_bb0150","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.cell.2012.03.043","article-title":"Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair","volume":"149","author":"D\u2019Angiolella","year":"2012","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107518_bb0155","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nsmb1267","article-title":"Role for BLM in replication-fork restart and suppression of origin firing after replicative stress","volume":"14","author":"Davies","year":"2007","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2016.00186","article-title":"Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR inhibition","volume":"6","author":"Deeg","year":"2016","journal-title":"Frontiers in Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107518_bb0165","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.1547007","article-title":"The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1","volume":"21","author":"Delacroix","year":"2007","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.11.002","article-title":"Mitotic catastrophe and cancer drug resistance: A link that must to be broken","volume":"24","author":"Denisenko","year":"2016","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0175","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/1878-0261.12402","article-title":"Fibroblast growth factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors","volume":"13","author":"Dias","year":"2019","journal-title":"Molecular Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107518_bb0180","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nm.1947","article-title":"Histone H2AX is integral to hypoxia-driven neovascularization","volume":"15","author":"Economopoulou","year":"2009","journal-title":"Nature Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107518_bb0185","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.1073\/pnas.1812410116","article-title":"Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion","volume":"116","author":"Elliott","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"42","key":"10.1016\/j.pharmthera.2020.107518_bb0190","doi-asserted-by":"crossref","first-page":"21956","DOI":"10.1074\/jbc.C116.747758","article-title":"Ewing tumor-associated Antigen 1 Interacts with Replication Protein A to Promote Restart of Stalled Replication Forks","volume":"291","author":"Feng","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"issue":"6219","key":"10.1016\/j.pharmthera.2020.107518_bb0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.1257216","article-title":"Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors","volume":"347","author":"Flynn","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death & Disease"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107518_bb0205","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107518_bb0210","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4155\/fmc.15.33","article-title":"Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer","volume":"7","author":"Foote","year":"2015","journal-title":"Future Medicinal Chemistry"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107518_bb0215","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and Characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107518_bb0220","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/bloodadvances.2017015214","article-title":"Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase","volume":"2","author":"Fordham","year":"2018","journal-title":"Blood Advances"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2018.03.005","article-title":"Targeting the replication stress response in cancer","volume":"188","author":"Forment","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13014-015-0464-y","article-title":"VE-821, an ATR inhibitor, causes radiosensitization in human tumor cells irradiated with high LET radiation","volume":"10","author":"Fujisawa","year":"2015","journal-title":"Radiation Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0235","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pharmthera.2012.10.009","article-title":"Targeting DNA repair mechanisms in cancer","volume":"137","author":"Furgason","year":"2013","journal-title":"Pharmacology & Therapeutics"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107518_bb0240","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0245","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","article-title":"DNA repair targeted therapy: The past or future of cancer treatment?","volume":"160","author":"Gavande","year":"2016","journal-title":"Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107518_bb0250","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41419-019-1689-8","article-title":"ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation","volume":"10","author":"Gomes","year":"2019","journal-title":"Cell Death & Disease"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0255","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.molcel.2014.12.003","article-title":"Interaction of Chk1 with Treslin negatively regulates the initiation of chromosomal DNA replication","volume":"57","author":"Guo","year":"2015","journal-title":"Molecular Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107518_bb0260","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.tcb.2015.04.001","article-title":"Hitting cancers\u2019 weak spots: vulnerabilities imposed by p53 mutation","volume":"25","author":"Gurpinar","year":"2015","journal-title":"Trends in Cell Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0265","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/ncb3422","article-title":"Activation of the ATR kinase by the RPA-binding protein ETAA1","volume":"18","author":"Haahr","year":"2016","journal-title":"Nature Cell Biology"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107518_bb0270","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107518_bb0275","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1074\/jbc.M611292200","article-title":"Cdc7-Dbf4 and the human S checkpoint response to UVC","volume":"282","author":"Heffernan","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0280","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fonc.2017.00098","article-title":"Targeting ongoing DNA damage in multiple myeloma: Effects of DNA damage response inhibitors on plasma cell survival","volume":"7","author":"Herrero","year":"2017","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107518_bb0285","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.apsb.2018.07.008","article-title":"Recent developments in topoisomerase-targeted cancer chemotherapy","volume":"8","author":"Hevener","year":"2018","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0290","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1124\/mol.112.080614","article-title":"Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination","volume":"82","author":"Huehls","year":"2012","journal-title":"Molecular Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107518_bb0295","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Research"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107518_bb0300","doi-asserted-by":"crossref","first-page":"8956","DOI":"10.1073\/pnas.0803978105","article-title":"Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication","volume":"105","author":"Ibarra","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2016.01.014","article-title":"Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs","volume":"162","author":"Jackson","year":"2016","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/ncb1337","article-title":"ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks","volume":"8","author":"Jazayeri","year":"2006","journal-title":"Nature Cell Biology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107518_bb0315","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41416-019-0565-8","article-title":"Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated\/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells","volume":"121","author":"Jette","year":"2019","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0320","article-title":"ATM in DNA repair in cancer","volume":"107391","author":"Jin","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107518_bb0325","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Joss\u00e9","year":"2014","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0330","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.trecan.2018.09.007","article-title":"Synthetically lethal interactions of ATM, ATR, and DNA-PKcs","volume":"4","author":"Kantidze","year":"2018","journal-title":"Trends in Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107518_bb0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1940-6207.CAPR-17-0053","article-title":"Piperlongumine induces reactive oxygen species (ROS)-dependent downregulation of specificity protein transcription factors","volume":"10","author":"Karki","year":"2017","journal-title":"Cancer Prevention Research"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107518_bb0340","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: Targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0345","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"Knegtel","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"issue":"26","key":"10.1016\/j.pharmthera.2020.107518_bb0350","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1038\/onc.2014.276","article-title":"ATR inhibition preferentially targets homologous recombination-deficient tumor cells","volume":"34","author":"Krajewska","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26825","article-title":"Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program","volume":"65","author":"Kurmasheva","year":"2018","journal-title":"Pediatric Blood & Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2020.107518_bb0360","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0140-6736(15)60373-7","article-title":"Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway","volume":"385","author":"Kwok","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0365","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41467-017-00221-3","article-title":"ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways","volume":"8","author":"Le","year":"2017","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107518_bb0370","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nature Reviews Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0375","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1091\/mbc.12.3.551","article-title":"Positive regulation of Wee1 by Chk1 and 14-3-3 proteins","volume":"12","author":"Lee","year":"2001","journal-title":"Molecular Biology of the Cell"},{"issue":"38","key":"10.1016\/j.pharmthera.2020.107518_bb0380","doi-asserted-by":"crossref","first-page":"28036","DOI":"10.1074\/jbc.M704635200","article-title":"The Rad9-Hus1-Rad1 checkpoint clamp regulates interaction of TopBP1 with ATR","volume":"282","author":"Lee","year":"2007","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0385","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2016.10.023","article-title":"Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer","volume":"121","author":"Leszczynska","year":"2016","journal-title":"Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology"},{"issue":"6330","key":"10.1016\/j.pharmthera.2020.107518_bb0390","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107518_bb0395","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.molcel.2013.07.023","article-title":"FANCD2 binds MCM proteins and controls replisome function upon activation of s phase checkpoint signaling","volume":"51","author":"Lossaint","year":"2013","journal-title":"Molecular Cell"},{"issue":"13 Supplement","key":"10.1016\/j.pharmthera.2020.107518_bb0400","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1158\/1538-7445.AM2017-983","article-title":"Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models","volume":"77","author":"Luecking","year":"2017","journal-title":"Cancer Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107518_bb0405","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0410","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2016.09.024","article-title":"Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy","volume":"383","author":"Massey","year":"2016","journal-title":"Cancer Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0415","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","article-title":"Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand","volume":"12","author":"Mei","year":"2019","journal-title":"Journal of Hematology & Oncology"},{"issue":"32","key":"10.1016\/j.pharmthera.2020.107518_bb0420","doi-asserted-by":"crossref","first-page":"32396","DOI":"10.18632\/oncotarget.6136","article-title":"Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition","volume":"6","author":"Middleton","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107518_bb0425","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/cancers10080275","article-title":"The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo- and radiosensitisation","volume":"10","author":"Middleton","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00635","article-title":"DNA-PK as an emerging therapeutic target in cancer","volume":"9","author":"Mohiuddin","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107518_bb0435","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","article-title":"ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency","volume":"74","author":"Mohni","year":"2014","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107518_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125482","article-title":"A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments","volume":"10","author":"Mohni","year":"2015","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0445","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gad.1666208","article-title":"TopBP1 activates ATR through ATRIP and a PIKK regulatory domain","volume":"22","author":"Mordes","year":"2008","journal-title":"Genes & Development"},{"issue":"36","key":"10.1016\/j.pharmthera.2020.107518_bb0450","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/onc.2015.521","article-title":"BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells","volume":"35","author":"Muralidharan","year":"2016","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107518_bb0455","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ng.420","article-title":"A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging","volume":"41","author":"Murga","year":"2009","journal-title":"Nature Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0460","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.201404111","article-title":"Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery","volume":"206","author":"Murphy","year":"2014","journal-title":"The Journal of Cell Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0465","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1535-7163.MCT-18-0972","article-title":"Inhibition of the replication stress response is a synthetic vulnerability in SCLC that acts synergistically in combination with cisplatin","volume":"18","author":"Nagel","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0470","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nrm3935","article-title":"Replication fork reversal in eukaryotes: from dead end to dynamic response","volume":"16","author":"Neelsen","year":"2015","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107518_bb0475","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1073\/pnas.161281798","article-title":"ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation","volume":"98","author":"Nghiem","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"35","key":"10.1016\/j.pharmthera.2020.107518_bb0480","doi-asserted-by":"crossref","first-page":"56826","DOI":"10.18632\/oncotarget.10862","article-title":"IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin","volume":"7","author":"O\u2019Flanagan","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107518_bb0485","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O\u2019Neil","year":"2017","journal-title":"Nature Reviews. Genetics"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107518_bb0490","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1158\/1078-0432.CCR-10-0286","article-title":"Targeting hypoxic cells through the DNA damage response","volume":"16","author":"Olcina","year":"2010","journal-title":"Clinical Cancer Research\u202f: An Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0495","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nature Reviews. Cancer"},{"issue":"5331","key":"10.1016\/j.pharmthera.2020.107518_bb0500","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.277.5331.1501","article-title":"Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216","volume":"277","author":"Peng","year":"1997","journal-title":"Science (New York, N.Y.)"},{"issue":"37","key":"10.1016\/j.pharmthera.2020.107518_bb0505","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.1005031107","article-title":"Chk1 promotes replication fork progression by controlling replication initiation","volume":"107","author":"Petermann","year":"2010","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107518_bb0510","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/sj.onc.1206169","article-title":"Werner\u2019s syndrome protein is phosphorylated in an ATR\/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle","volume":"22","author":"Pichierri","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0515","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjc.2012.265","article-title":"Targeting radiation-resistant hypoxic tumour cells through ATR inhibition","volume":"107","author":"Pires","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0520","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pharmthera.2013.12.010","article-title":"Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors","volume":"142","author":"Pitts","year":"2014","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0525","doi-asserted-by":"crossref","first-page":"14135","DOI":"10.1038\/s41598-019-50509-1","article-title":"Antileukemic activity of novel adenosine derivatives","volume":"9","author":"Poczta","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0530","series-title":"Handbook of radiobiology","author":"Prasad","year":"1995"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0535","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cbt.21093","article-title":"The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy","volume":"13","author":"Prevo","year":"2012","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0540","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bcp.2019.04.022","article-title":"Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis","volume":"164","author":"Qi","year":"2019","journal-title":"Biochemical Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0545","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107518_bb0550","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nature Chemical Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0555","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12885-017-3319-0","article-title":"Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids","volume":"17","author":"Riffle","year":"2017","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107518_bb0560","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0565","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","article-title":"A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors","volume":"62","author":"Ruiz","year":"2016","journal-title":"Molecular Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107518_bb0570","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107518_bb0575","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.3390\/ijms150712007","article-title":"Radiosensitization of human leukemic HL-60 cells by ATR kinase inhibitor (VE-821): phosphoproteomic analysis","volume":"15","author":"\u0160alovsk\u00e1","year":"2014","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107518_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199349","article-title":"Radio-sensitizing effects of VE-821 and beyond: Distinct phosphoproteomic and metabolomic changes after ATR inhibition in irradiated MOLT-4 cells","volume":"13","author":"\u0160alovsk\u00e1","year":"2018","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0585","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.celrep.2015.12.032","article-title":"Cancer-specific synthetic lethality between ATR and CHK1 kinase activities","volume":"14","author":"Sanjiv","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0590","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.dnarep.2015.04.030","article-title":"Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment","volume":"32","author":"Scanlon","year":"2015","journal-title":"DNA Repair"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107518_bb0595","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1158\/0008-5472.CAN-16-1479","article-title":"Gemcitabine mechanism of action confounds early assessment of treatment response by 3\u2032-deoxy-3\u2032-[18F]fluorothymidine in preclinical models of lung cancer","volume":"76","author":"Schelhaas","year":"2016","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0600","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM deficiency is associated with sensitivity to PARP1- and ATR inhibitors in lung adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0605","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI58928","article-title":"Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR","volume":"122","author":"Schoppy","year":"2012","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0610","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.06.010","article-title":"The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma","volume":"432","author":"Shi","year":"2018","journal-title":"Cancer Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107518_bb0615","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/15384101.2017.1404206","article-title":"ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage","volume":"17","author":"Song","year":"2018","journal-title":"Cell Cycle (Georgetown, Tex.)"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107518_bb0620","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"S\u00f8rensen","year":"2003","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0625","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/sj.leu.2400632","article-title":"Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus","volume":"11","author":"Stanulla","year":"1997","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107518_bb0630","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1158\/0008-5472.CAN-03-3207","article-title":"ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation","volume":"64","author":"Stiff","year":"2004","journal-title":"Cancer Research"},{"issue":"6846","key":"10.1016\/j.pharmthera.2020.107518_bb0635","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/35087607","article-title":"Regulation of DNA replication fork progression through damaged DNA by the Mec1\/Rad53 checkpoint","volume":"412","author":"Tercero","year":"2001","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107518_bb0640","doi-asserted-by":"crossref","first-page":"8395","DOI":"10.1074\/jbc.RA119.008154","article-title":"Common motifs in ETAA1 and TOPBP1 required for ATR kinase activation","volume":"294","author":"Thada","year":"2019","journal-title":"Journal of Biological Chemistry"},{"issue":"16","key":"10.1016\/j.pharmthera.2020.107518_bb0645","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0650","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10495-017-1422-y","article-title":"Piperlongumine induces G2\/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway","volume":"22","author":"Thongsom","year":"2017","journal-title":"Apoptosis"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107518_bb0655","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molcel.2017.05.001","article-title":"Replication catastrophe: When a checkpoint fails because of exhaustion","volume":"66","author":"Toledo","year":"2017","journal-title":"Molecular Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0660","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs","volume":"5","author":"Toledo","year":"2011","journal-title":"Molecular Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107518_bb0665","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nature Structural & Molecular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107518_bb0670","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0675","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-18-0470","article-title":"ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer","author":"Tu","year":"2018","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0680","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nature Reviews Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107518_bb0685","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00411-013-0486-5","article-title":"Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60)","volume":"52","author":"V\u00e1vrov\u00e1","year":"2013","journal-title":"Radiation and Environmental Biophysics"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107518_bb0690","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrg2159","article-title":"Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins","volume":"8","author":"Wang","year":"2007","journal-title":"Nature Reviews. Genetics"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107518_bb0695","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1074\/jbc.RA118.005188","article-title":"DNA polymerase \u03b8 (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse","volume":"294","author":"Wang","year":"2019","journal-title":"Journal of Biological Chemistry"},{"issue":"51","key":"10.1016\/j.pharmthera.2020.107518_bb0700","doi-asserted-by":"crossref","first-page":"47759","DOI":"10.1074\/jbc.C100569200","article-title":"Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress","volume":"276","author":"Ward","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0705","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0710","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107518_bb0715","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijrobp.2019.06.2508","article-title":"Preclinical combination studies of an FGFR2 targeted Thorium-227 conjugate and the ATR inhibitor BAY 1895344","volume":"105","author":"Wickstroem","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107518_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.09.016","article-title":"A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening","volume":"23","author":"Yan","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107518_bb0730","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-genet-121415-121658","article-title":"Functions, regulation, and therapeutic implications of the ATR checkpoint pathway","volume":"50","author":"Yazinski","year":"2016","journal-title":"Annual Review of Genetics"},{"issue":"13 Supplement","key":"10.1016\/j.pharmthera.2020.107518_bb0735","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1538-7445.AM2019-369","article-title":"Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy","volume":"79","author":"Zenke","year":"2019","journal-title":"Cancer Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107518_bb0740","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ncb3013","article-title":"ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1","volume":"16","author":"Zhang","year":"2014","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107518_bb0745","doi-asserted-by":"crossref","first-page":"109661","DOI":"10.1016\/j.biopha.2019.109661","article-title":"Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer","volume":"123","author":"Zheng","year":"2020","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107518_bb0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003702","article-title":"An essential function for the ATR-activation-domain (AAD) of TopBP1 in mouse development and cellular senescence","volume":"9","author":"Zhou","year":"2013","journal-title":"PLoS Genetics"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:05:53Z","timestamp":1759010753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820300462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":150,"alternative-id":["S0163725820300462"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107518","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107518"}}